JP2006516272A - 医薬品組成物 - Google Patents
医薬品組成物 Download PDFInfo
- Publication number
- JP2006516272A JP2006516272A JP2006500187A JP2006500187A JP2006516272A JP 2006516272 A JP2006516272 A JP 2006516272A JP 2006500187 A JP2006500187 A JP 2006500187A JP 2006500187 A JP2006500187 A JP 2006500187A JP 2006516272 A JP2006516272 A JP 2006516272A
- Authority
- JP
- Japan
- Prior art keywords
- fentanyl
- composition according
- pectin
- composition
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
(i)フェンタニルまたは薬学的に許容されるその塩、並びに
(ii)(a)ペクチン、及び(b)ポロクサマーと、キトサンまたはその塩もしくは誘導体、
から選ばれる薬学的に許容される添加物の水溶液を有する組成物を提供するものである。但し、前記構成物がペクチンを有する場合は、2価のイオン、特にカルシウムイオンなどのペクチンをゲル化させる試薬を含まない。
(a)ペクチン及び
(b)ポロクサマーと、キトサンまたはその塩もしくは誘導体;
から選ばれる薬学的に許容される添加剤の使用であって、フェンタニルまたは薬学的に許容されるその塩をヒトなどの動物に経鼻送達するのための薬剤の製造における使用であって、前記薬剤はフェンタニルの血漿濃度ピークが、同量のフェンタニル用量の単純な水溶液の経鼻投与により得られる場合に対して10〜80%であるように調整されている、添加剤を提供するものである。
(a)ペクチン及び
(b)ポロクサマーと、キトサンまたはその塩もしくは誘導体;
から選ばれる薬学的に許容される添加剤の使用であって、激痛または慢性痛の治療、予防または管理に好適な、ヒトなどの動物におけるフェンタニル及び薬学的に許容されるその塩を経鼻送達するための薬剤の製造において、前記薬剤はフェンタニルの血漿濃度ピークが、同量のフェンタニル用量の単純な水溶液の経鼻投与により得られる場合に対して10〜80%であるように調整されている、添加剤の使用を提供する。
2gのペクチン(Slendid 100, CP Kelco, デンマーク)を、180mlの水に撹拌しながら溶解させた。1mlのフェニルエチルアルコール(R. C. Treat, イギリス)及び40mgのプロピルヒドロキシ安息香酸(Nipa Laboratories, イギリス)を防腐剤として加えた。314mgのクエン酸フェンタニル(MacFarlan Smith,エジンバラ、イギリス)及び8.3gのマンニトール(Sigma, Poole,イギリス)をペクチン溶液に溶解させ、200mlのメスフラスコに移し、水でメスアップした。得られた溶液のpHは4.2、重量オスモル濃度は0.33osmol/kgであった。
4gのペクチン(Slendid 100)を180mlの水に撹拌しながら溶解させた。1mlのフェニルエチルアルコール及び40mgのプロピルヒドロキシ安息香酸をペクチン溶液に加えた。314mgのクエン酸フェンタニル及び8.3gのマンニトールをペクチン溶液に溶解させ、200mlのメスフラスコに移し、水でメスアップした。
300mgの50%塩化ベンザルコニウム水溶液(Albright & Wilson, イギリス)を秤量して10mlのメスフラスコに移し、約8mlの水に分散させた後10mlにメスアップして、15mg/mlの塩化ベンザルコニウム溶液を調製した。
2.5gのペクチン(Slendid 100)を200mlの水に撹拌して溶解させた。1.25mlのフェニルエチルアルコールと50mgのプロピルヒドロキシ安息香酸をペクチン溶液に加えた。1.58mgのアミノ酸フェンタニルと9gのマンニトールをペクチン溶液に溶解させ、250mlのメスフラスコに移して水でメスアップした。
3の経鼻フェンタニル処方及び経粘膜トローチ処方(ActiqR, Elan Pharmaceuticals, UK)について臨床試験を行い、薬物動力学的な効力を評価した。
Claims (23)
- 動物に対するフェンタニルまたは薬学的に許容されるその塩の経鼻送達のための組成物であって、前記組成物は、
(i)フェンタニルまたは薬学的に許容されるその塩と、
(ii)(a)ペクチン、または(b)ポロクサマー及び、キトサンもしくはその塩か誘導体、である薬学的に許容される添加剤の水溶液を有し、
前記組成物がペクチンを有する場合には2価の金属イオンを実質的に含まず、
同量のフェンタニルを単純な水溶液を用いて経鼻投与した場合との比較において前記組成物は、同量のフェンタニルを単純な水溶液を用いて経鼻投与した場合に対して10〜80%のフェンタニルの血漿濃度ピーク(Cmax)が得られる、組成物。 - 同量のフェンタニルを単純な水溶液を用いて経鼻投与した場合との比較において前記組成物は、同量のフェンタニルを単純な水溶液を用いて経鼻投与した場合に対して30〜70%のフェンタニルの血漿濃度ピーク(Cmax)が得られる、請求項1に記載の組成物。
- 薬学的に許容されるフェンタニルの塩を有する、請求項1または2に記載の組成物。
- 前記薬学的に許容されるフェンタニルの塩は、クエン酸フェンタニルである、請求項3に記載の組成物。
- ペクチンを有する、請求項1〜4の何れか1項に記載の組成物。
- 前記ペクチンはDE値が7〜30%である、請求項5に記載の組成物。
- 前記ペクチンの濃度は5〜25mg/mlである、請求項5または6に記載の組成物。
- 2価の金属イオンが少なくとも99%フリーである、請求項5〜7の何れか1項に記載の組成物。
- 重量オスモル濃度が0.25〜0.35osmol/kgである、請求項5〜8の何れか1項に記載の組成物。
- pHが3.4〜5.0である、請求項5〜9の何れか1項に記載の組成物。
- ポロクサマー及びキトサンまたはその塩もしくは誘導体を有する、請求項1〜4の何れか1項に記載の組成物。
- グルタミン酸キトサンを有する、請求項11に記載の組成物。
- ポロクサマーの濃度は80〜120mg/mlであり、キトサンまたはその塩もしくは誘導体の濃度は1〜10mg/ml(キトサンとして表示)である、請求項11または12に記載の組成物。
- 重量オスモル濃度が0.4〜0.7osmol/kgである、請求項11〜13の何れか1項に記載の組成物。
- pHが3.0〜5.0である、請求項11〜14の何れか1項に記載の組成物。
- フェンタニルまたは薬学的に許容されるその塩の濃度が0.2〜15mg/ml(フェンタニルとして表示)である、請求項1〜15の何れか1項に記載の組成物。
- 滴液または噴霧の形態によって鼻へ送達するように構成された、請求項1〜16の何れか1項に記載の組成物。
- 激痛または慢性痛の治療または予防に用いられる、請求項1〜17の何れか1項に記載の組成物。
- (a)ペクチン、及び
(b)ポロクサマーと、キトサンまたはその塩もしくは誘導体
から選択される薬学的に許容できる添加剤の使用であって、
フェンタニル及び薬学的に許容されるその塩を必要としている患者へ経鼻送達するための薬剤の製造における使用であって、前記薬剤は、同量のフェンタニル用量の単純な水溶液を用いて得られる場合に対して10〜80%のフェンタニルの血漿濃度ピーク(Cmax)が得られるように構成されている、添加剤の使用。 - 激痛または慢性痛の治療または予防のための薬剤の製造における、請求項19に記載の使用。
- 激痛または慢性痛の治療または予防のための方法であって、前記方法は請求項1〜18の何れか1項に記載の組成物の経鼻送達を有する、方法。
- 請求項1〜18の何れか1項に記載の組成物を装填した噴霧装置。
- 請求項1〜18の何れか1項に記載の組成物を調整するための方法であって、フェンタニルまたは薬学的に許容できるその塩を薬学的に許容できる前記添加剤と水中にて混合することを有する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0300531.1A GB0300531D0 (en) | 2003-01-10 | 2003-01-10 | Pharmaceutical compositions |
GB0300531.1 | 2003-01-10 | ||
PCT/GB2004/000057 WO2004062561A2 (en) | 2003-01-10 | 2004-01-12 | Pharmaceutical compositions comprising fentanyl for intranasal delivery |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006516272A true JP2006516272A (ja) | 2006-06-29 |
JP2006516272A5 JP2006516272A5 (ja) | 2011-07-28 |
JP4827725B2 JP4827725B2 (ja) | 2011-11-30 |
Family
ID=9950919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006500187A Expired - Fee Related JP4827725B2 (ja) | 2003-01-10 | 2004-01-12 | 医薬品組成物 |
Country Status (26)
Country | Link |
---|---|
US (5) | US20040166067A1 (ja) |
EP (2) | EP1635783B1 (ja) |
JP (1) | JP4827725B2 (ja) |
KR (3) | KR20050103275A (ja) |
CN (1) | CN100423709C (ja) |
AU (1) | AU2004204381B2 (ja) |
BR (1) | BRPI0406674B8 (ja) |
CA (1) | CA2511974C (ja) |
CY (1) | CY1115056T1 (ja) |
DK (1) | DK1635783T5 (ja) |
EA (1) | EA008500B1 (ja) |
ES (2) | ES2432119T3 (ja) |
FR (1) | FR14C0020I1 (ja) |
GB (1) | GB0300531D0 (ja) |
GE (1) | GEP20084340B (ja) |
HK (1) | HK1088555A1 (ja) |
IL (1) | IL169480A (ja) |
MX (1) | MXPA05007333A (ja) |
NO (1) | NO335127B1 (ja) |
NZ (1) | NZ541018A (ja) |
PL (1) | PL212950B1 (ja) |
PT (2) | PT2436375T (ja) |
SI (1) | SI1635783T1 (ja) |
UA (1) | UA85050C2 (ja) |
WO (1) | WO2004062561A2 (ja) |
ZA (1) | ZA200505274B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011503044A (ja) * | 2007-11-09 | 2011-01-27 | アルキメデス・デベロップメント・リミテッド | 鼻腔内組成物 |
JP2012504999A (ja) * | 2008-10-08 | 2012-03-01 | アルキメデス ディヴェロプメント リミテッド | 液体鎮痛薬投与用デバイス |
US9731869B2 (en) | 2011-02-04 | 2017-08-15 | Archimedes Development Limited | Container |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002009707A1 (en) * | 2000-07-31 | 2002-02-07 | Nycomed Danmark A/S | Fentanyl composition for nasal administration |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
US20050129679A1 (en) | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
CZ302789B6 (cs) | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
CN107260672A (zh) | 2011-05-13 | 2017-10-20 | 欧洲凯尔特公司 | 包含纳洛酮的鼻内药物剂型 |
ES2748632T3 (es) | 2012-10-03 | 2020-03-17 | Proponent Biotech Gmbh | Composición farmacéutica que comprende ácido propiónico para uso en el tratamiento de infecciones víricas |
JP6820743B2 (ja) | 2013-09-05 | 2021-01-27 | エイビー2 バイオ ソシエテアノニム | 炎症性疾患におけるil−18結合タンパク質(il−18bp) |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
MX2017010919A (es) | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
EP3568126B1 (en) * | 2017-01-11 | 2023-11-01 | Torrent Pharmaceuticals Limited | Tapentadol nasal composition |
US11207309B2 (en) | 2019-07-19 | 2021-12-28 | Hikma Pharmaceuticals International Limited | Ready-to-administer fentanyl formulations |
US11160799B2 (en) * | 2019-10-22 | 2021-11-02 | Cessatech A/S | Pediatric combination |
US20230173021A1 (en) | 2020-05-06 | 2023-06-08 | Ab2 Bio Sa | IL-18 Binding Protein (IL-18BP) In Respiratory Diseases |
GB202007404D0 (en) | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
WO2023067348A1 (en) | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
WO2023166206A1 (en) | 2022-03-04 | 2023-09-07 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in the treatment of vexas |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524094A (ja) * | 1997-04-18 | 2001-11-27 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | 粘膜表面への改良された薬物供給 |
WO2002000195A2 (en) * | 2000-06-26 | 2002-01-03 | Epicept Corporation | Methods and compositions for treating pain of the mucous membrane |
WO2002009707A1 (en) * | 2000-07-31 | 2002-02-07 | Nycomed Danmark A/S | Fentanyl composition for nasal administration |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2125212A (en) * | 1938-05-03 | 1938-07-26 | Vick Chemical Company | Therapeutic composition |
US2730483A (en) * | 1952-08-12 | 1956-01-10 | Nepera Chemical Co Inc | Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine |
BE623427A (ja) * | 1961-10-10 | |||
US3184600A (en) | 1963-05-07 | 1965-05-18 | Potter Instrument Co Inc | Photosensitive apparatus for measuring coordinate distances |
JPS5885813A (ja) * | 1981-11-17 | 1983-05-23 | Toyo Jozo Co Ltd | 吸収性良好な製剤 |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
US4486423A (en) * | 1983-04-21 | 1984-12-04 | Janssen Pharmaceutica Inc. | Stable fentanyl composition |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5122127A (en) | 1985-05-01 | 1992-06-16 | University Of Utah | Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues |
HU193780B (en) * | 1985-06-21 | 1987-11-30 | Richter Gedeon Vegyeszet | Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JPS62123112A (ja) * | 1985-11-22 | 1987-06-04 | Sunstar Inc | 軟膏基剤 |
DE3601132A1 (de) * | 1986-01-16 | 1987-07-23 | Christian Bannert | Verfahren zur behandlung der schleimhaut |
JPS62236862A (ja) | 1986-04-09 | 1987-10-16 | Nippon Kayaku Co Ltd | 人工粘液 |
ZA875317B (en) | 1986-08-01 | 1988-01-25 | Warner-Lambert Company | Transdermal compositions |
ATE77559T1 (de) | 1986-11-14 | 1992-07-15 | Theratech Inc | Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems. |
US4826683A (en) * | 1987-01-09 | 1989-05-02 | Bates Harry L | Decongestant |
US5200180A (en) * | 1987-06-26 | 1993-04-06 | Christian Bannert | Pharmaceutical composition for the treatment of the human eye |
DE3726797A1 (de) * | 1987-08-12 | 1989-02-23 | Bayer Ag | Arzneimittel fuer den bereich der mundhoehle |
US4915948A (en) | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
DE3827561C1 (ja) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
GB8900267D0 (en) | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
GB8904370D0 (en) | 1989-02-25 | 1989-04-12 | Cosmas Damian Ltd | Liquid delivery compositions |
JP2911496B2 (ja) * | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
NL9000634A (nl) | 1990-03-20 | 1991-10-16 | Catharina Ziekenhuis Stichting | Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding. |
US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
EP0491076A1 (en) | 1990-12-19 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols |
JPH0597706A (ja) | 1991-04-09 | 1993-04-20 | Chemex Block Drug Jv | アフタ性潰瘍および他の粘膜皮膚障害の処置方法 |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
EP0571671B1 (en) | 1992-05-26 | 1997-09-17 | The Procter & Gamble Company | A Pharmaceutical composition in powder form |
EP0651993B1 (en) | 1992-07-23 | 2002-10-09 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneously administrable base composition and drug composition prepared therefrom |
WO1994010987A1 (en) | 1992-11-09 | 1994-05-26 | Pharmetrix Corporation | Combined analgesic delivery methods for pain management |
US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
EP0865789B1 (en) | 1993-03-26 | 2005-03-16 | Franciscus Wilhelmus Henricus Maria Merkus | Pharmaceutical compositions for intranasal administration of dihydroergotamine |
GB9310412D0 (en) | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
SE9301877D0 (sv) | 1993-06-02 | 1993-06-02 | Kabi Pharmacia Ab | In situ gel for therapeutic use |
BR9407397A (pt) | 1993-07-12 | 1996-11-05 | Virus Res Inst | Vacinas microencapsuladas em hidrogel |
US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
GB9406171D0 (en) * | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
DK0752855T3 (da) * | 1994-03-30 | 2000-01-03 | Gs Dev Ab | Anvendelse af fedtsyreestere som bioadhæsive substanser |
DE69528165T2 (de) | 1994-04-21 | 2003-05-15 | Hisamitsu Pharmaceutical Co | Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel |
JP3911290B2 (ja) * | 1994-05-13 | 2007-05-09 | アラダイム コーポレーション | エアゾールを含む麻酔用処方 |
GB9414966D0 (en) | 1994-07-26 | 1994-09-14 | Danbiosyst Uk | Pharmaceutical compositions for the nasal administration of antiviral agents |
FR2733420B1 (fr) | 1995-04-28 | 1997-06-27 | Sep Tarral | Preparations pectiques utilisables comme support de medicament |
US6881208B1 (en) | 1995-06-05 | 2005-04-19 | Joseph B. Phipps | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
DK0836511T3 (da) | 1995-06-05 | 2004-08-09 | Alza Corp | Anordning for transdermal elektrotransportafgivelse af fentanyl og sufentanil |
IE960375A1 (en) | 1995-06-05 | 1996-12-11 | Alza Corp | Device for transdermal electrotransport delivery of fentanyl¹and sufentanil |
JP3098401B2 (ja) | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
DE19527411A1 (de) * | 1995-07-27 | 1997-01-30 | Ackermann & Schmitt Gmbh & Co | Kupplung |
US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
WO1998002187A1 (en) | 1996-07-11 | 1998-01-22 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
US6667279B1 (en) | 1996-11-13 | 2003-12-23 | Wallace, Inc. | Method and composition for forming water impermeable barrier |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
GB2328443B (en) | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
DE69831421T2 (de) | 1997-12-02 | 2006-06-22 | Archimedes Development Ltd. | Zusammensetzungen zur nasalen verabreichung |
US6090368A (en) | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
EP1108423B1 (en) | 1998-08-26 | 2005-03-30 | Teijin Limited | Powdery pernasal compositions |
SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
JP2000229859A (ja) | 1999-02-12 | 2000-08-22 | Teijin Ltd | 安定なブプレノルフィン経鼻製剤 |
US6541021B1 (en) | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
JP2001002589A (ja) | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
US6663883B1 (en) * | 1999-08-26 | 2003-12-16 | Takeda Chemical Industries, Ltd. | Matrix adhering to nasal mucosa |
JP2001089359A (ja) | 1999-09-24 | 2001-04-03 | Toko Yakuhin Kogyo Kk | 鎮痛成分の点鼻用ゲルまたはゾル製剤 |
GB9924797D0 (en) * | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
ES2326730T3 (es) | 2000-02-08 | 2009-10-19 | Euro-Celtique S.A. | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas. |
AU2001243414B2 (en) | 2000-03-10 | 2005-05-19 | Durect Corporation | Opioid formulations |
AU2001262992A1 (en) | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
EP1296649A2 (en) | 2000-06-22 | 2003-04-02 | Pharmasol Limited | Pharmaceutical compositions comprising an opioid analgesic |
DE10064219B9 (de) | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung |
US6777000B2 (en) | 2001-02-28 | 2004-08-17 | Carrington Laboratories, Inc. | In-situ gel formation of pectin |
GB2378383A (en) | 2001-06-06 | 2003-02-12 | Gursharan Moonga | Nasal delivery of pharmaceutical compositions in powder form |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
-
2003
- 2003-01-10 GB GBGB0300531.1A patent/GB0300531D0/en not_active Ceased
-
2004
- 2004-01-08 US US10/753,628 patent/US20040166067A1/en not_active Abandoned
- 2004-01-12 SI SI200432094T patent/SI1635783T1/sl unknown
- 2004-01-12 ES ES04701381T patent/ES2432119T3/es not_active Expired - Lifetime
- 2004-01-12 MX MXPA05007333A patent/MXPA05007333A/es active IP Right Grant
- 2004-01-12 AU AU2004204381A patent/AU2004204381B2/en active Active
- 2004-01-12 PL PL377823A patent/PL212950B1/pl unknown
- 2004-01-12 EP EP04701381.8A patent/EP1635783B1/en not_active Expired - Lifetime
- 2004-01-12 WO PCT/GB2004/000057 patent/WO2004062561A2/en active Application Filing
- 2004-01-12 KR KR1020057012821A patent/KR20050103275A/ko active Search and Examination
- 2004-01-12 DK DK04701381.8T patent/DK1635783T5/da active
- 2004-01-12 BR BRPI0406674A patent/BRPI0406674B8/pt active IP Right Grant
- 2004-01-12 GE GEAP20048931A patent/GEP20084340B/en unknown
- 2004-01-12 ES ES11185114T patent/ES2721899T3/es not_active Expired - Lifetime
- 2004-01-12 PT PT11185114T patent/PT2436375T/pt unknown
- 2004-01-12 JP JP2006500187A patent/JP4827725B2/ja not_active Expired - Fee Related
- 2004-01-12 PT PT47013818T patent/PT1635783E/pt unknown
- 2004-01-12 UA UAA200507799A patent/UA85050C2/ru unknown
- 2004-01-12 KR KR1020097010700A patent/KR101012148B1/ko active IP Right Grant
- 2004-01-12 EP EP11185114.3A patent/EP2436375B1/en not_active Expired - Lifetime
- 2004-01-12 CA CA2511974A patent/CA2511974C/en not_active Expired - Fee Related
- 2004-01-12 KR KR1020107021362A patent/KR20100118144A/ko active IP Right Grant
- 2004-01-12 CN CNB200480002000XA patent/CN100423709C/zh not_active Expired - Lifetime
- 2004-01-12 NZ NZ541018A patent/NZ541018A/en not_active IP Right Cessation
- 2004-01-12 EA EA200501105A patent/EA008500B1/ru not_active IP Right Cessation
-
2005
- 2005-06-24 NO NO20053119A patent/NO335127B1/no not_active IP Right Cessation
- 2005-06-29 IL IL169480A patent/IL169480A/en active IP Right Grant
- 2005-06-29 ZA ZA2005/05274A patent/ZA200505274B/en unknown
-
2006
- 2006-09-20 HK HK06110437.4A patent/HK1088555A1/xx not_active IP Right Cessation
-
2008
- 2008-03-13 US US12/047,388 patent/US8216604B2/en active Active
-
2012
- 2012-07-03 US US13/541,325 patent/US9078814B2/en not_active Expired - Fee Related
- 2012-07-03 US US13/541,314 patent/US8889176B2/en not_active Expired - Fee Related
-
2013
- 2013-12-04 CY CY20131101096T patent/CY1115056T1/el unknown
-
2014
- 2014-03-13 FR FR14C0020C patent/FR14C0020I1/fr active Active
-
2015
- 2015-06-23 US US14/747,289 patent/US9814705B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524094A (ja) * | 1997-04-18 | 2001-11-27 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | 粘膜表面への改良された薬物供給 |
WO2002000195A2 (en) * | 2000-06-26 | 2002-01-03 | Epicept Corporation | Methods and compositions for treating pain of the mucous membrane |
WO2002009707A1 (en) * | 2000-07-31 | 2002-02-07 | Nycomed Danmark A/S | Fentanyl composition for nasal administration |
Non-Patent Citations (2)
Title |
---|
JPN6010012669, Zhou,M.,et al, International Journal of Pharmaceutics, 1996, Vol.135, pages 115−125 * |
JPN6010012673, Soane,R.J.,et al, International Journal of Pharmaceutics, 1999, Vol.178, pages 55−65 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011503044A (ja) * | 2007-11-09 | 2011-01-27 | アルキメデス・デベロップメント・リミテッド | 鼻腔内組成物 |
JP2012504999A (ja) * | 2008-10-08 | 2012-03-01 | アルキメデス ディヴェロプメント リミテッド | 液体鎮痛薬投与用デバイス |
US9731869B2 (en) | 2011-02-04 | 2017-08-15 | Archimedes Development Limited | Container |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9814705B2 (en) | Intranasal spray device containing pharmaceutical composition | |
US20080248991A1 (en) | Chitosan Containing Solution | |
NO335348B1 (no) | Blanding for nasal administrering omfattende granisetron, anvendelse av granisetron og anordning for nasal administrering. | |
AU2005212355B2 (en) | Controlled release formulations | |
CN101757625A (zh) | 环糊精包合皮质激素和h1受体拮抗剂的鼻用药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060829 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060829 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110308 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110606 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110816 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110913 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140922 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4827725 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |